Imperial College London


Faculty of MedicineDepartment of Surgery & Cancer




+44 (0)20 3313 3759eric.aboagye




Mrs Maureen Francis +44 (0)20 7594 2793




GN1Commonwealth BuildingHammersmith Campus






BibTex format

author = {Przystal, J and Waramit, S and Pranjol, MZI and Yan, W and Chu, G and Chongchai, A and Samarth, G and Olaciregui, N and Tabatabai, G and Carcaboso, A and Aboagye, E and Suwan, K and Hajitou, A},
doi = {10.15252/emmm.201708492},
journal = {EMBO Molecular Medicine},
title = {Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma},
url = {},
volume = {11},
year = {2019}

RIS format (EndNote, RefMan)

AB - Glioblastoma multiforme (GBM) is the most lethal primary intracranial malignant neoplasm in adults and most resistant to treatment. Integration of gene therapy and chemotherapy, chemovirotherapy, has the potential to improve treatment. We have introduced an intravenous bacteriophage (phage) vector for dual targeting of therapeutic genes to glioblastoma. It is a hybrid AAV/phage, AAVP, designed to deliver a recombinant adenoassociated virus genome (rAAV) by the capsid of M13 phage. In this vector, dual tumor targeting is first achieved by phage capsid display of the RGD4C ligand that binds the αvβ3 integrin receptor. Second, genes are expressed from a tumoractivated and temozolomide (TMZ)induced promoter of the glucoseregulated protein, Grp78. Here, we investigated systemic combination therapy using TMZ and targeted suicide gene therapy by the RGD4C/AAVPGrp78. Firstly, in vitro we showed that TMZ increases endogenous Grp78 gene expression and boosts transgene expression from the RGD4C/AAVPGrp78 in human GBM cells. Next, RGD4C/AAVPGrp78 targets intracranial tumors in mice following intravenous administration. Finally, combination of TMZ and RGD4C/AAVPGrp78 targeted gene therapy exerts a synergistic effect to suppress growth of orthotopic glioblastoma.
AU - Przystal,J
AU - Waramit,S
AU - Pranjol,MZI
AU - Yan,W
AU - Chu,G
AU - Chongchai,A
AU - Samarth,G
AU - Olaciregui,N
AU - Tabatabai,G
AU - Carcaboso,A
AU - Aboagye,E
AU - Suwan,K
AU - Hajitou,A
DO - 10.15252/emmm.201708492
PY - 2019///
SN - 1757-4676
TI - Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma
T2 - EMBO Molecular Medicine
UR -
UR -
VL - 11
ER -